Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to boost cancer pill adherence in poor communities

NCT ID NCT03245411

Knowledge-focused Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how to help cancer patients from low-income and low-literacy backgrounds take their oral chemotherapy pills correctly. Researchers will test different support strategies to see which ones work best. The goal is to reduce missed doses and improve overall care for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients on oral chemotherapeutic agents * Clinical diagnosis of stage IV breast cancer * Clinical diagnosis of stage III and IV colorectal cancer (not receiving concurrent radiation therapy) * Clinical diagnosis of stage IV non-small cell lung cancer * Clinical diagnosis of stage IV renal cell carcinoma * Clinical diagnosis of stage IV ovarian carcinoma * Clinical diagnosis of multiple myeloma * Clinical diagnosis of chronic myelogenous leukemia on TKI * Clinical diagnosis of myelodysplastic syndrome on Lenalidomide * Adjuvant treatment for Gastro Intestinal Stromal Tumor * Clinical diagnosis of chronic Lymphocytic Leukemia * Clinical diagnosis of metastatic Prostate cancer * Clinical diagnosis of hepatocellular Carcinoma * Clinical diagnosis of stage IV Melanoma * Clinical diagnosis of myelofibrosis/myeloproliferative neoplasms * Age \>18 years * ECOG Performance Status \<3 Exclusion Criteria: * ECOG Performance Status of 3 and above * Concurrent chemo radiation * Non-English speaker * Clinical diagnosis of dementia, or otherwise unable to give informed consent. * History of non-compliance (defined as the history of 2 or more missed appointments in the clinic). * Pregnant patients * Nursing Home Patients * Incarcerated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Albert Einstein Healthcare Network

    RECRUITING

    Philadelphia, Pennsylvania, 19141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.